Orphelia Pharma SA   Report issue

For profit Phase 1
Founded: Paris France (2007)
Status: No NME R&D (2007)

Organization Overview

First Clinical Trial
2014
NCT02220114
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Orphelia Pharma

Active Ingredients

Drugs in Phase 1 Trials (2)

temozolomide (temodar) (2 trials)

vigabatrin (sabril) (2 trials)

Indications

Overview

  • Highest Phase: Phase 1
  • # of Trials: 4
  • # of Trial APIs: 2